Comparative Pharmacology
Head-to-head clinical analysis: CARISOPRODOL versus STRIFON FORTE DSC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARISOPRODOL versus STRIFON FORTE DSC.
CARISOPRODOL vs STRIFON FORTE DSC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carisoprodol is a centrally acting skeletal muscle relaxant that exerts its effects via modulation of GABA-A receptors, possibly through its active metabolite meprobamate, which is a controlled substance with barbiturate-like activity. It also inhibits interneuronal activity in the descending reticular formation and spinal cord, leading to muscle relaxation.
Caffeine is a central nervous system stimulant that acts as an antagonist at adenosine receptors (A1 and A2A subtypes), thereby reducing the inhibitory effects of adenosine. Dihydroergotamine is an ergot alkaloid with partial agonist activity at serotonin 5-HT1B/1D receptors, leading to vasoconstriction of cranial blood vessels. Thioridazine is a typical antipsychotic with high affinity for dopamine D2 receptors and moderate affinity for serotonin 5-HT2A, alpha1-adrenergic, and histamine H1 receptors.
250-350 mg orally 3 times daily and at bedtime
Chlorzoxazone 500 mg to 750 mg orally three to four times daily.
None Documented
None Documented
Clinical Note
moderateCarisoprodol + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Carisoprodol is combined with Fluticasone propionate."
Clinical Note
moderateCarisoprodol + Fluconazole
"The metabolism of Fluconazole can be decreased when combined with Carisoprodol."
Clinical Note
moderateCarisoprodol + Clotrimazole
"The metabolism of Clotrimazole can be decreased when combined with Carisoprodol."
Clinical Note
moderateCarisoprodol + Ketoconazole
Terminal elimination half-life is approximately 2.0 hours for carisoprodol; the active metabolite meprobamate has a half-life of 6-12 hours. Clinical context: Short half-life supports three-times-daily dosing; accumulation of meprobamate with repeated dosing or renal impairment may prolong effects.
10-12 hours in healthy adults; prolonged to 18-24 hours in hepatic impairment or elderly
Renal: >99% as metabolites (hydroxycarisoprodol and meprobamate) and minor unchanged drug. Fecal: <1%. Biliary: negligible.
Renal excretion of unchanged drug (70-90%) and glucuronide conjugates; biliary/fecal elimination accounts for <10%
Category A/B
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant
"The metabolism of Ketoconazole can be decreased when combined with Carisoprodol."